Vitamin D 20, per Week for Five Years Does Not Prevent Progression From Prediabetes to Diabetes.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Who Took Part

PubMed indexes the participants as middle-aged adults, both men and women.

Five hundred eleven subjects (mean age 62 y, 314 males) with prediabetes diagnosed with an oral glucose tolerance test as part of the Tromsø Study 2007–2008 were included.

Twenty-nine subjects in the vitamin D and 24 in the placebo group withdrew because of adverse events.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

This was a randomized controlled trial performed in 2008 through 2015.

The study was conducted at the clinical research unit at a teaching hospital.

A total of 256 were randomized to vitamin D and 255 to placebo.

Annual oral glucose tolerance tests were performed.

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 2, Dietary Supplements, Glucose Tolerance Test, Glycated Hemoglobin, Insulin Resistance and Prediabetic State.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2016 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.